Here we go again. The U.S. Food and Drug Administration’s decision earlier this month to withdraw approval for the cancer drug Avastin for treating women with advanced breast cancer was met with ...
Onvansertib combined with FOLFIRI and Avastin shows dose-dependent improvements in tumor response and disease control for RAS-mutated mCRC. Cardiff Oncology plans a registrational trial to compare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results